Discover a groundbreaking path forward in the fight against dementia with this vital resource, which bridges the gap between costly drug discovery and the transformative potential of harnessing the immune system to finally target the underlying mechanisms of Alzheimer s disease. Alzheimer s disease, which is characterized by a progressive loss of memory and cognitive function, is the most prevalent type of dementia in adults. Despite being widespread, there is currently no permanent treatment for this condition. Current drugs provide only symptomatic relief with serious adverse consequences. The process of discovering new medications in this field is costly and time-consuming, so despite effort on the part of the scientific and pharmaceutical communities, few Alzheimer s medications have been created. This book offers a comprehensive exploration of how the immune system can be harnessed to combat one of the most challenging neurodegenerative disorders of our time. It examines the scientific foundations of immunotherapy, including antibody-based strategies, vaccine development, and modulation of innate and adaptive immune responses. It highlights the interplay between amyloid and tau pathology, neuroinflammation, and microglial activation, providing readers with a clear understanding of the mechanisms driving therapeutic innovation. Beyond the laboratory, this volume bridges preclinical research with clinical applications, addressing safety, efficacy, and regulatory considerations. Case studies, emerging technologies, and future directions are presented to illustrate both the promise and the challenges of immunotherapy in Alzheimer s care. Designed for neuroscientists, pharmacologists, clinicians, and biotechnology professionals, the book serves as a vital resource for those seeking evidence-based insights into cutting-edge therapeutic approaches that may transform the landscape of Alzheimer s treatment.
